| Literature DB >> 22988507 |
Nina Hovanec1, Anuradha Sawant, Tom J Overend, Robert J Petrella, Anthony A Vandervoort.
Abstract
Objective. This paper analyzes the effects of resistance training (RT) on metabolic, neuromuscular, and cardiovascular functions in older adults (mean age ≥ 65 years) with type 2 diabetes (T2DM). Research Design and Methods. A systematic review conducted by two reviewers of the published literature produced 3 records based on 2 randomized controlled trials that assessed the effect of RT on disease process measures and musculoskeletal/body composition measures. Statistical, Comprehensive Meta-Analysis (version 2) software was used to compute Hedge's g, and results were calculated using the random effects model to account for methodological differences amongst studies. Results. Largest effect of RT was seen on muscle strength; especially lower body strength, while the point estimate effect on body composition was small and not statistically significant. The cumulative point estimate for the T2DM disease process measures was moderate and statistically significant. Conclusions. RT generally had a positive effect on musculoskeletal, body composition, and T2DM disease processes measures, with tentative conclusions based on a low number of completed RCTs. Thus, more research is needed on such programs for older adults (≥65 years) with T2DM.Entities:
Year: 2012 PMID: 22988507 PMCID: PMC3440926 DOI: 10.1155/2012/284635
Source DB: PubMed Journal: J Aging Res ISSN: 2090-2204
Figure 1Chronological Timeline of PA Recommendations for T2DM from Various Professional Organizations [modified from [26]]. PHAC [Public Health Agency of Canada]; CSEP [Canadian Society for Exercise Physiology]; CDA [Canadian Diabetes Association]; ACSM [American College of Sports Medicine]; ADA [American Diabetes Association]; CDC [Centers for Disease Control and Prevention]; AHA [American Heart Association]. PA [Physical Activity]; RT [resistance training]; AT [aerobic training]; UE [upper extremity]; LE [lower extremity]; HRmax [maximum heart rate]; VO2max [maximal oxygen uptake/consumption]; d [days]; w [week]; w/t [with]; reps [repetitions]; ex [exercises]; h [hour]; min. [minute].
Outcome measures.
| Body composition measures | Musculoskeletal measures | Type 2 diabetes process measures |
|---|---|---|
| Whole body lean tissue mass (kg) | Muscle strength | Fasting glucose (mmol/L) |
Study characteristics.
| Study ID (reference number), PEDro score | Sample | Intervention (duration, frequency, intensity, session duration, sets of reps, equipment: exercises) | Outcome measure (¥
| Authors conclusion |
|---|---|---|---|---|
| *Brooks et al. [ | Exercise: | (i)16 weeks | Whole-body lean tissue mass (0.04) | 16 weeks of RT resulted in musculoskeletal and metabolic improvements, and it is a mode of exercise worth considering as an adjunct to SC |
|
| ||||
| *Castaneda et al. [ | Exercise: | (i) 16 weeks | Whole body fat mass (0.26) | RT was feasible among older adults with type 2 diabetes, and it resulted in improved metabolic control |
|
| ||||
| Dunstan et al. [ | Exercise: | (i) 24 weeks | Total cholesterol (N/A) | A 16-week progressive, high-intensity RT program was effective in improving glycemic control and muscle strength in older adults with T2DM |
RT: resistance training; SC: standard care; d: days; min: minutes; sec: seconds; b/w: between; reps: repetitions; UE: upper extremity;
LE: lower extremity; CSA: cross sectional area; HbA1c: glycosylated hemoglobin; WL: weight loss).
*Brooks et al. [17] and Castaneda et al. [13] include the same intervention and participants but different outcome measures.
¥ P value reported by the authors.
PEDro rating details.
| Study ID (PEDro score) | Random allocation | Concealed allocation | Baseline comparability | Blind subjects | Blind therapists | Blind assessors | Adequate followup | Intention-to-treat analysis | Between-group comparisons | Point estimates and variability |
|---|---|---|---|---|---|---|---|---|---|---|
| Brooks et al. (7) [ | Yes | No | Yes | No | No | Yes | Yes | Yes | Yes | Yes |
| Castaneda et al. (6) [ | Yes | No | No | No | No | Yes | Yes | Yes | Yes | Yes |
| Dunstan et al. (4) [ | Yes | No | Yes | No | No | No | No | No | Yes | Yes |
Figure 2Study selection diagram [50] AT-aerobic training.
Participant characteristics.
| Source | Group ( | Age (years) | Gender (M/F) | Whole body fat mass (kg) | BMI (kg/m2) | Diabetes | HbA1c (%) | Fasting glucose (mmol/L) | Fasting insulin (pmol/L) |
|---|---|---|---|---|---|---|---|---|---|
| *Brooks et al. [ | Exercise 31 | 66 ± 11.1 | 10/21 | 35 ± 5.6 | 30.9 ± 6.1 | 8 ± 5.6 | 8.7 ± 5.6 | 8.79 ± 2.7 | 116 ± 167.4 |
|
Dunstan et al. [ | Exercise 16 | 67.6 ± 5.2 | 10/6 | 33.1 ± 7.4 | 31.5 ± 3.7 | 7.6 ± 5.4 | 8.1 ± 1 | 9.5 ± 2.3 | 132.9 ± 63 |
All measures are provided as means ± SD.
*Brooks et al. [17] and Castaneda et al. [13] included the same cohort of participants.
Heterogeneity for moderator variables.
| Variable |
| df ( |
|
|---|---|---|---|
| All disease process measures | 42.387 | 19 | 0.002 |
| BP | 2.171 | 3 | 0.538 |
| Fasting glucose | 0.364 | 1 | 0.546 |
| Fasting insulin | 0.181 | 2 | 0.913 |
| HbA1c | 3.099 | 2 | 0.212 |
| HDL | 0.055 | 1 | 0.814 |
| Total cholesterol and LDL | 3.079 | 3 | 0.380 |
| All musculoskeletal measures | 31.313 | 11 | 0.001 |
| Muscle quality | 8.184 | 4 | 0.085 |
| Muscle strength | 2.675 | 2 | 0.262 |
| Body composition | 3.256 | 3 | 0.354 |
Summary of resistance training effect on outcome measures.
| Outcome | Hedge's |
| Effect description (statistical significance) | ||
|---|---|---|---|---|---|
| Disease processes | −0.271¥ | 0.008 | Medium (significant) | ||
| BP (systolic/diastolic mmHg) | − 0.540 | <0.001 | Large (significant) | ||
| HbA1c (%) | −0.463 | 0.145 | Medium (not significant) | ||
| Total and LDL cholesterol | −0.464 | 0.002 | medium (significant) | ||
| Fasting glucose | −0.121 | 0.559 | Small (not significant) | ||
| Fasting insulin | 0.505 | 0.016 | Medium (significant) | ||
| HDL cholesterol | 0.134 | 0.517 | Small (not significant) | ||
| Body composition | 0.199 | 0.197 | Small (not significant) | ||
| Lean body mass | 0.395 | 0.220 | Small (not significant) | ||
| Fat body mass | 0.066 | 0.749 | Small (not significant) | ||
| Muscle strength | 1.05 | <0.001 | Large (significant) | ||
| Lower body muscle strength | 1.415 | <0.001 | Large (significant) | ||
| Upper body muscle strength | 0.974 | <0.001 | Large (significant) | ||
| Whole body muscle strength | 0.802 | 0.002 | Large (significant) | ||
|
| |||||
| *Further muscle measures | Exercise | Control |
| ||
|
| |||||
| Quality | Baseline | 61 ± 27.8 | 51 ± 22.3 | <0.001 | |
| Final | 100 ± 33.4 | 48 ± 22.3 | |||
| Type I CSA ( | Baseline | 4068 ± 1425.3 | 4546 ± 1503.3 | 0.04 | |
| Final | 4928 ± 2071.2 | 4381 ± 1692.6 | |||
| Type II CSA ( | Baseline | 3885 ± 1547.8 | 4330 ± 1926.4 | 0.04 | |
| Final | 4605 ± 1575.7 | 4201 ± 1870.8 | |||
BP-blood pressure; HbA1c: glycosylated hemoglobin; LDL: low density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; CSA: cross sectional area.
¥Negative values denote a decrease in the outcome measure (i.e., this is a positive effect, since a reduction in disease processes, such as lowered BP, LDL, and HBA1c, indicates an improvement in disease management).
*Further muscle measures were not entered into CMA; all values are means ± SE, taken from [17].